Opportunité en vedette
Imaging Amyloid Beta in the Retina
University of Waterloo
BackgroundAmyloid Beta protein is a marker for Alzheimer’s disease. Currently the only definitive test occurs during an autopsy. There are other forms of dementia that have similar symptoms to Alzheimer’s but which cannot be ruled out while the patient is still alive.If there were a means for earlier detection of the Amyloid Beta protein then it would be possible to properly diagnose patients with Alzheimer’s disease and start treatment at an earlier stage. This would lead...Opportunité en vedette
Tissue Engineered Blood Vessels as a Model for Drug Discovery in Alzheimer’s Disease
Université de la Colombie-Britannique
Humanized 3D blood vessels are improved in vitro tools for cerebrovascular studies Model for Alzheimer’s disease and blood brain barrier function Screening system for therapeutic candidates that target Aβ deposition or enhance Aβ clearance Screening system for therapeutic candidates that target apoE secretion Alzheimer’s disease (AD) is a chronic neurodegenerative disease that progressively affects memory, behavior and intellectual abilities. Between 60-90% of AD brains show evidence of...Opportunité en vedette
Damona Pharmaceuticals - Treat & Prevent Cognitive Deficits across Brain Disorders and During Aging
Centre for Addiction and Mental Health
Damona Pharmaceuticals (www.damonapharma.com) is a neuroscience pharma spin off company developing small molecules for the treatment of cognitive symptoms in depression. Its lead compound is a first in class novel small molecule in late pre-clinical development which has demonstrated drug like properties and efficacy in the treatment and prevention of cognitive symptoms in depression. The company is seeking strategic partnerships and investment to expedite the completion of the remaining...Opportunité en vedette
Combined Therapy for the Treatment of Parkinson's Disease.
Université Laval
DescriptionParkinson's disease is the second most common neurodegenerative disease after Alzheimer. It is attributable to a loss of dopamine. No cure for Parkinson's disease is known. Treatments available are symptomatic. Levodopa is one of the most effective medication for controlling motor impairment of Parkinson's disease patients. However, as the loss of dopamine-producing nerve cells continues, symptoms continue to worsen and consequently, the dose of levodopa has to be increased. This...Opportunité en vedette
Vaccine composition and its use against a motor neuron disease and/or a neurodegenerative disease associated with SOD1 abnormalities
Université Laval
Description Multiple approaches have been tested in ALS mouse models including pharmacological and virus-mediated delivery of molecules. The proposed immunotherapy approach is based on recent evidence of secretion of SOD1 and of toxicity of extracellular SOD1. Accordingly, the presumption is that reduction of extracellular SOD1 mutant molecules would alleviate ALS disease in a manner analogous to immunisation with amyloid protein in models of Alzheimer’s disease. Indeed, immunisation...Opportunité en vedette